Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

Company Overview

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders. These products illustrate Ultragenyx’s approach of targeting well-defined genetic defects with therapies designed to correct or mitigate the underlying cause of disease. Ultragenyx maintains a robust clinical pipeline, with investigational treatments in various stages of development for conditions such as congenital hyperinsulinism, pyruvate kinase deficiency and other rare enzymatic or metabolic disorders.

Ultragenyx operates globally, with a commercial presence in the United States, Europe and Canada, and research collaborations spanning multiple continents. The company works closely with patient advocacy groups and academic centers to support clinical trials and foster patient access. Under the leadership of founder and Chief Executive Officer Emil Kakkis—an experienced clinician-scientist in the rare disease field—Ultragenyx continues to expand its capabilities in manufacturing, regulatory affairs and global commercialization to deliver transformative therapies for underserved patient populations.

Key Stats

• Today's Range: $31.60 to $33.57
• 50-Day Range: $27.39 to $33.43
• 52-Week Range: $25.81 to $57.99
• Volume: 1.57 million shs
• Average Volume: 1.69 million shs
• Market Capitalization: $3.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $81.50
• Consensus Rating: Moderate Buy

Ultragenyx Pharmaceutical Stock Analysis - MarketRank™

Ultragenyx Pharmaceutical scored higher than 89% of companies evaluated by MarketBeat, and ranked 129th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ultragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 11 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Ultragenyx Pharmaceutical has a consensus price target of $81.50, representing about 143.8% upside from its current price of $33.43.

Amount of Analyst Coverage

Ultragenyx Pharmaceutical has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($5.18) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ultragenyx Pharmaceutical is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ultragenyx Pharmaceutical is -6.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ultragenyx Pharmaceutical has a P/B Ratio of 12.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.25% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.

Short Interest Ratio / Days to Cover

Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ultragenyx Pharmaceutical has recently decreased by 4.45%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ultragenyx Pharmaceutical does not currently pay a dividend.

Dividend Growth

Ultragenyx Pharmaceutical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -2.28

Percentage of Shares Shorted

8.25% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.

Short Interest Ratio / Days to Cover

Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ultragenyx Pharmaceutical has recently decreased by 4.45%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.86

News Sentiment

Ultragenyx Pharmaceutical has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Ultragenyx Pharmaceutical this week, compared to 10 articles on an average week.

Search Interest

13 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $328,486.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Ultragenyx Pharmaceutical is held by insiders.

Percentage Held by Institutions

97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RARE Stock Analysis - Frequently Asked Questions

How have RARE shares performed this year?

Ultragenyx Pharmaceutical's stock was trading at $42.07 at the beginning of the year. Since then, RARE stock has decreased by 20.5% and is now trading at $33.43.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. The business's revenue for the quarter was up 13.2% compared to the same quarter last year.
Read the conference call transcript.

Who are Ultragenyx Pharmaceutical's major shareholders?

Top institutional shareholders of Ultragenyx Pharmaceutical include Assenagon Asset Management S.A. (0.26%), Wedge Capital Management L L P NC (0.04%), Voya Investment Management LLC (0.02%) and Woodstock Corp (0.02%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, John Richard Pinion, Howard Horn, Dennis Karl Huang, Karah Herdman Parschauer, Eric Crombez, Erik Harris, Theodore Alan Huizenga, Camille L Bedrosian, Corazon (Corsee) D Sanders and Matthew K Fust.
View institutional ownership trends.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RARE
• CIK: 1515673
• Web: www.ultragenyx.com
• Phone: (415) 483-8800
• Fax: 415-483-8810
• Employees: 1,294
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Ultragenyx Pharmaceutical: $81.50
• High Price Target: $128.00
• Low Price Target: $34.00
• Potential Upside/Downside: +143.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$569.18 million
• Net Margins: -87.34%
• Pretax Margin: -86.93%
• Return on Equity: -237.48%
• Return on Assets: -37.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.45
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $560.23 million
• Price / Sales: 5.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.76 per share
• Price / Book: 12.11

Miscellaneous

• Outstanding Shares: 96,370,000
• Free Float: 91,072,000
• Market Cap: $3.22 billion
• Optionable: Optionable
• Beta: 0.21